Mirum's Heavy Dependence on Livmarli for Revenues Remains a Woe [Yahoo! Finance]
Mirum Pharmaceuticals, Inc. - common stock (MIRM)
Last mirum pharmaceuticals, inc. - common stock earnings: 3/12 04:02 pm
Check Earnings Report
Company Research
Source: Yahoo! Finance
for the treatment of cholestatic pruritus in patients with Alagille syndrome worldwide. The drug is also approved for treating certain patients with progressive familial intrahepatic cholestasis in the United States and Europe. Sales of Livmarli have been rising steadily since its approval and launch worldwide. In 2024, Livmarli generated sales worth $213.3 million, reflecting an increase of 50.4% on a year-over-year basis. Though Livmarli is witnessing continued demand and driving the top line, the company's high dependence on the drug remains a concern. In the past year, shares of Mirum have surged 83.2% against the industry's decline of 8.5%. Image Source: Zacks Investment Research Mirum is evaluating Livmarli in the phase III EXPAND study for treati
Read more
Impact Snapshot
Event Time:
MIRM
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
MIRM alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
MIRM alerts
High impacting Mirum Pharmaceuticals, Inc. - common stock news events
Weekly update
A roundup of the hottest topics
MIRM
News
- LIVMARLI Now Approved in Japan for ALGS and PFIC [Yahoo! Finance]Yahoo! Finance
- LIVMARLI Now Approved in Japan for ALGS and PFICBusiness Wire
- Mirum Pharmaceuticals: Set Fair For Share Price Momentum - Reversing My Sell Call [Seeking Alpha]Seeking Alpha
- Mirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)Business Wire
- Analyst Estimates: Here's What Brokers Think Of Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM) After Its Full-Year Report [Yahoo! Finance]Yahoo! Finance
MIRM
Earnings
- 11/12/24 - Beat
MIRM
Sec Filings
- 3/19/25 - Form 4
- 3/18/25 - Form 4
- 3/18/25 - Form 4
- MIRM's page on the SEC website